These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 25883396)
41. Orphan drugs and the NHS: should we value rarity? McCabe C; Claxton K; Tsuchiya A BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305 [TBL] [Abstract][Full Text] [Related]
42. One drug to treat many diseases: unlocking the economic trap of rare diseases. Pierzynowska K; Kamińska T; Węgrzyn G Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291 [TBL] [Abstract][Full Text] [Related]
43. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers. Ollendorf DA; Chapman RH; Pearson SD Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351 [TBL] [Abstract][Full Text] [Related]
44. How should we model rare disease allocation decisions? London AJ Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383 [No Abstract] [Full Text] [Related]
45. Rare diseases: the bane of modern society and the quest for cures. Azie N; Vincent J Clin Pharmacol Ther; 2012 Aug; 92(2):135-9. PubMed ID: 22814654 [TBL] [Abstract][Full Text] [Related]
46. The many vs. the few. Menzel PT Hastings Cent Rep; 2012; 42(5):5-6; author reply 8-9. PubMed ID: 23050290 [No Abstract] [Full Text] [Related]
47. The many vs. the few. Loewenstein G Hastings Cent Rep; 2012; 42(5):7-8; author reply 8-9. PubMed ID: 23050293 [No Abstract] [Full Text] [Related]
48. The many vs. the few. Wells RJ Hastings Cent Rep; 2012; 42(5):7; author reply 8-9. PubMed ID: 23050292 [No Abstract] [Full Text] [Related]
49. Orphan drug development: an economically viable strategy for biopharma R&D. Meekings KN; Williams CS; Arrowsmith JE Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309 [TBL] [Abstract][Full Text] [Related]
51. [Orphan drugs and drug pirates]. Bannenberg WJ; 't Hoen EFM Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749801 [TBL] [Abstract][Full Text] [Related]
52. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
53. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access? Rawson NSB J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580 [TBL] [Abstract][Full Text] [Related]
54. Commissioning for rare diseases: view from the frontline. Burls A; Austin D; Moore D BMJ; 2005 Oct; 331(7523):1019-21. PubMed ID: 16254306 [TBL] [Abstract][Full Text] [Related]
55. Duel over discounts. Pharma, providers at odds over 'orphan drugs'. Daly R Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763 [No Abstract] [Full Text] [Related]
56. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession]. Janzen RW; Ludwig WD; Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801 [TBL] [Abstract][Full Text] [Related]
57. Orphan economics: the downside of supplyside pharmacology. Samson K Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669 [No Abstract] [Full Text] [Related]
58. Economic considerations in the provision of treatments for rare diseases. McCabe C; Edlin R; Round J Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448 [TBL] [Abstract][Full Text] [Related]
59. The rising cost of orphan drugs. Lancet Haematol; 2015 Nov; 2(11):e456. PubMed ID: 26686251 [No Abstract] [Full Text] [Related]
60. The balancing act of orphan drug pricing. The Lancet Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]